Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23230946 | 0.99 | NPC1 (0.71) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL23230469 | 0.97 | NPC1 (0.64) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL2752905 | 0.85 | RAB9A (0.61) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL2751842 | 0.83 | RAB9A (0.70) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL23736045 | 0.83 | RAB9A (0.79) | NPC1RAB9AEPHX1SMN1; SMN2KMT2A | |
| SCHEMBL2750640 | 0.82 | RAB9A (0.97) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL18615685 | 0.81 | EPHX2 (0.62) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL27264917 | 0.81 | RAB9A (1.00) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL27267057 | 0.81 | RAB9A (1.00) | NPC1RAB9APOLBEPHX1SMN1; SMN2 | |
| SCHEMBL8777821 | 0.80 | RAB9A (0.77) | NPC1RAB9APOLBEPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178570-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20060293342-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293342-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | NPC1 4467/4885RAB9A 3880/4885POLB 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.